What is Novavax's product sales — total revenue?

Novavax (NVAX) reported product sales — total revenue of $18.85M in Q2 2026.

How has Novavax's product sales — total revenue changed year-over-year?

Novavax's product sales — total revenue increased by 75.8% year-over-year, from $10.72M to $18.85M.

What does product sales — total revenue mean?

This metric represents the total gross revenue recognized from the sale of vaccine products within the specified business segment. It serves as a primary indicator of the company's commercial success and market adoption of its clinical-stage vaccine portfolio.

Novavax (NVAX) Product sales — Total Revenue

Screener

Other product segments

Licensing, royalties, and other

$37.84M-83.4%

Cost reimbursements

$22.6M+249%

Upfront fee amortization

$8.73M-28.9%

Milestones amortization

$3.76M-33.6%

Royalties

$700K-86.0%

Support services

$265K-4.7%

Milestones

$0-100%

Upfront fee

$0-100%

Similar metrics at other companies

MRNANet product sales — Total Revenue

$352M+309%

CRMDProduct sales, net — Total Revenue

$121.92M+212%

BIIBMS Product Revenues — Total Revenue

$963.3M-13.0%

ADBEProduct — Total Revenue

$89M+1.1%

CIENProduct — Total Revenue

$1.31B+46.0%

DLXProduct — Total Revenue

$237M-15.8%

Other financials

Income statement

See full

Revenue$56.7M-76.3%

Gross profit$42.5M-81.0%

Operating income-$54.9M-154%

Net income-$53.4M-150%

EPS (diluted)-$0.32-152%

Balance sheet

See full

Cash & equivalents$191.5M-24.5%

Total debt$297.3M+413%

Total equity-$190.7M-607%

Total assets$955.6M-28.5%

Cash flow

See full

Operating cash flow-$72.8M+42.9%

CapEx$588.0K+11.6%

Free cash flow-$73.4M+42.7%

Valuation

See full

Market cap$1.27B+3.7%

Enterprise value$1.38B+33.6%

P/S3.1×+1.9×

Profitability

See full

Gross margin78.6%-9.6pp

Operating margin-56.6%-89.2pp

Net margin-59.9%-99.1pp

FCF margin-59%-61.5pp

Returns & leverage

See full

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Novavax’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 7:50 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001000694-26-000018

Line item	For the Three Months Ended June 30, 2026	For the Three Months Ended June 30, 2025	For the Six Months Ended June 30, 2026	For the Six Months Ended June 30, 2025
Revenue:
Product sales	$18,854	$10,724	$61,054	$632,402
Licensing, royalties, and other	37,844	228,516	135,158	273,493
Total revenue	56,698	239,240	196,212	905,895
Expenses:
Cost of sales	14,246	15,325	44,941	29,439
Research and development	70,693	79,233	166,165	168,170
Selling, general, and administrative	26,665	43,612	55,442	91,702

Item 1. Consolidated Financial Statements

FAQ

What is Novavax's product sales — total revenue?: Novavax (NVAX) reported product sales — total revenue of $18.85M in Q2 2026.
How has Novavax's product sales — total revenue changed year-over-year?: Novavax's product sales — total revenue increased by 75.8% year-over-year, from $10.72M to $18.85M.
What does product sales — total revenue mean?: This metric represents the total gross revenue recognized from the sale of vaccine products within the specified business segment. It serves as a primary indicator of the company's commercial success and market adoption of its clinical-stage vaccine portfolio.